288 related articles for article (PubMed ID: 31504526)
1. Immunogenicity of High Dose Influenza Vaccine for Patients with Inflammatory Bowel Disease on Anti-TNF Monotherapy: A Randomized Clinical Trial.
Caldera F; Hillman L; Saha S; Wald A; Grimes I; Zhang Y; Sharpe AR; Reichelderfer M; Hayney MS
Inflamm Bowel Dis; 2020 Mar; 26(4):593-602. PubMed ID: 31504526
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy.
Shirai S; Hara M; Sakata Y; Tsuruoka N; Yamamoto K; Shimoda R; Gomi Y; Yoshii H; Fujimoto K; Iwakiri R
Inflamm Bowel Dis; 2018 Apr; 24(5):1082-1091. PubMed ID: 29538682
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease.
deBruyn JC; Hilsden R; Fonseca K; Russell ML; Kaplan GG; Vanderkooi O; Wrobel I
Inflamm Bowel Dis; 2012 Jan; 18(1):25-33. PubMed ID: 21472826
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.
Launay O; Abitbol V; Krivine A; Slama LB; Bourreille A; Dupas JL; Hébuterne X; Savoye G; Deplanque D; Bouhnik Y; Pelletier AL; Galtier F; Laharie D; Nachury M; Zerbib F; Allez M; Bommelaer G; Duclos B; Lucht F; Gougeon ML; Tartour E; Rozenberg F; Hanslik T; Beaugerie L; Carrat F;
J Crohns Colitis; 2015 Dec; 9(12):1096-107. PubMed ID: 26351392
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial.
deBruyn J; Fonseca K; Ghosh S; Panaccione R; Gasia MF; Ueno A; Kaplan GG; Seow CH; Wrobel I
Inflamm Bowel Dis; 2016 Mar; 22(3):638-47. PubMed ID: 26595551
[TBL] [Abstract][Full Text] [Related]
6. Immune response to influenza vaccine in children with inflammatory bowel disease.
Lu Y; Jacobson DL; Ashworth LA; Grand RJ; Meyer AL; McNeal MM; Gregas MC; Burchett SK; Bousvaros A
Am J Gastroenterol; 2009 Feb; 104(2):444-53. PubMed ID: 19174786
[TBL] [Abstract][Full Text] [Related]
7. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants.
Andrisani G; Frasca D; Romero M; Armuzzi A; Felice C; Marzo M; Pugliese D; Papa A; Mocci G; De Vitis I; Rapaccini GL; Blomberg BB; Guidi L
J Crohns Colitis; 2013 May; 7(4):301-7. PubMed ID: 22673636
[TBL] [Abstract][Full Text] [Related]
8. Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib.
Liu Z; Alexander JL; Yee Eng K; Ibraheim H; Anandabaskaran S; Saifuddin A; Constable L; Castro Seoane R; Bewshea C; Nice R; D'Mello A; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Hart AL; Lees CW; Goodhand JR; Kennedy NA; Pollock KM; Ahmad T; Powell N
J Crohns Colitis; 2024 Apr; 18(4):560-569. PubMed ID: 37941436
[TBL] [Abstract][Full Text] [Related]
9. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial.
Matsumoto H; Ohfuji S; Watanabe K; Yamagami H; Fukushima W; Maeda K; Kamata N; Sogawa M; Shiba M; Tanigawa T; Tominaga K; Watanabe T; Fujiwara Y; Hirota Y; Arakawa T
J Gastroenterol; 2015 Aug; 50(8):876-86. PubMed ID: 25672513
[TBL] [Abstract][Full Text] [Related]
10. Cell-Mediated Immune Responses After Influenza Vaccination of Solid Organ Transplant Recipients: Secondary Outcomes Analyses of a Randomized Controlled Trial.
L'huillier AG; Ferreira VH; Hirzel C; Natori Y; Slomovic J; Ku T; Hoschler K; Ierullo M; Selzner N; Schiff J; Singer LG; Humar A; Kumar D
J Infect Dis; 2020 Jan; 221(1):53-62. PubMed ID: 31550354
[TBL] [Abstract][Full Text] [Related]
11. Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years.
McLean HQ; Levine MZ; King JP; Flannery B; Belongia EA
Vaccine; 2021 Dec; 39(49):7146-7152. PubMed ID: 34774360
[TBL] [Abstract][Full Text] [Related]
12. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease.
Mamula P; Markowitz JE; Piccoli DA; Klimov A; Cohen L; Baldassano RN
Clin Gastroenterol Hepatol; 2007 Jul; 5(7):851-6. PubMed ID: 17544875
[TBL] [Abstract][Full Text] [Related]
13. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.
Cullen G; Bader C; Korzenik JR; Sands BE
Gut; 2012 Mar; 61(3):385-91. PubMed ID: 21757451
[TBL] [Abstract][Full Text] [Related]
14. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial.
Jamshed S; Walsh EE; Dimitroff LJ; Santelli JS; Falsey AR
Vaccine; 2016 Jan; 34(5):630-635. PubMed ID: 26721330
[TBL] [Abstract][Full Text] [Related]
15. Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy.
Bálint A; Farkas K; Éva PK; Terhes G; Urbán E; Szucs M; Nyári T; Bata Z; Nagy F; Szepes Z; Miheller P; Lorinczy K; Lakatos PL; Lovász B; Tamás S; Kulcsár A; Berényi A; Törocsik D; Daróczi T; Saródi Z; Wittmann T; Molnár T
Scand J Gastroenterol; 2015 Feb; 50(2):174-81. PubMed ID: 25384624
[TBL] [Abstract][Full Text] [Related]
16. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.
Nace DA; Lin CJ; Ross TM; Saracco S; Churilla RM; Zimmerman RK
J Infect Dis; 2015 Jun; 211(12):1915-24. PubMed ID: 25525051
[TBL] [Abstract][Full Text] [Related]
17. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.
Noh JY; Jang YS; Lee SN; Choi MJ; Yoon JG; Yu DH; Song JY; Cheong HJ; Kim WJ
Vaccine; 2019 Aug; 37(36):5171-5176. PubMed ID: 31377075
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
[TBL] [Abstract][Full Text] [Related]
19. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
